TW201124385A - Selective synthesis of functionalized pyrimidines - Google Patents

Selective synthesis of functionalized pyrimidines Download PDF

Info

Publication number
TW201124385A
TW201124385A TW099127176A TW99127176A TW201124385A TW 201124385 A TW201124385 A TW 201124385A TW 099127176 A TW099127176 A TW 099127176A TW 99127176 A TW99127176 A TW 99127176A TW 201124385 A TW201124385 A TW 201124385A
Authority
TW
Taiwan
Prior art keywords
group
reaction
formula
compound
doc
Prior art date
Application number
TW099127176A
Other languages
English (en)
Chinese (zh)
Inventor
Guenter Linz
Gerd Kraemer
Sabrina Kusserow
Juergen Schnaubelt
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42712695&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW201124385(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of TW201124385A publication Critical patent/TW201124385A/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/34One oxygen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
TW099127176A 2009-08-14 2010-08-13 Selective synthesis of functionalized pyrimidines TW201124385A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09167934 2009-08-14

Publications (1)

Publication Number Publication Date
TW201124385A true TW201124385A (en) 2011-07-16

Family

ID=42712695

Family Applications (1)

Application Number Title Priority Date Filing Date
TW099127176A TW201124385A (en) 2009-08-14 2010-08-13 Selective synthesis of functionalized pyrimidines

Country Status (17)

Country Link
US (1) US8933227B2 (OSRAM)
EP (1) EP2464634B1 (OSRAM)
JP (1) JP5539519B2 (OSRAM)
KR (1) KR20120046248A (OSRAM)
CN (1) CN102471287A (OSRAM)
AR (1) AR077925A1 (OSRAM)
AU (1) AU2010283713A1 (OSRAM)
BR (1) BR112012002971A2 (OSRAM)
CA (1) CA2767965A1 (OSRAM)
CL (1) CL2012000278A1 (OSRAM)
EA (1) EA201200282A1 (OSRAM)
IL (1) IL217112A0 (OSRAM)
IN (1) IN2012DN01342A (OSRAM)
MX (1) MX2012001469A (OSRAM)
NZ (1) NZ597538A (OSRAM)
TW (1) TW201124385A (OSRAM)
WO (1) WO2011018518A1 (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2268621A1 (en) * 2008-03-20 2011-01-05 Boehringer Ingelheim International GmbH Regioselective preparation of substituted pyrimidines
UY31714A (es) * 2008-03-20 2009-11-10 Boehringer Ingelheim Int Preparación selectiva de pirimidinas sustituidas
US8933227B2 (en) 2009-08-14 2015-01-13 Boehringer Ingelheim International Gmbh Selective synthesis of functionalized pyrimidines
US8729265B2 (en) 2009-08-14 2014-05-20 Boehringer Ingelheim International Gmbh Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives
CN102887860B (zh) * 2012-09-29 2015-07-01 上海泰坦科技有限公司 4-氯-6-三氟甲基嘧啶类化合物的制备方法
JP6391985B2 (ja) * 2014-05-16 2018-09-19 東ソー・ファインケム株式会社 2−置換−4−(2,2,2−トリフルオロエトキシ)−5−(トリフルオロメチル)ピリミジン誘導体及びその製造方法
JP6391988B2 (ja) * 2014-05-21 2018-09-19 東ソー・ファインケム株式会社 5−(トリフルオロメチル)ピリミジン誘導体の製造方法及び新規5−(トリフルオロメチル)ピリミジン誘導体
JP6262079B2 (ja) * 2014-06-02 2018-01-17 東ソー・ファインケム株式会社 4−(2,2,2−トリフルオロエトキシ)−5−(トリフルオロメチル)ピリミジン誘導体及びその製造方法
JP6431294B2 (ja) * 2014-06-16 2018-11-28 東ソー・ファインケム株式会社 5−(トリフルオロメチル)ピリミジン誘導体及びその製造法
JP6479486B2 (ja) * 2015-01-16 2019-03-06 東ソー・ファインケム株式会社 4−アルコキシ−5−(トリフルオロメチル)ピリミジン誘導体及びその製造方法

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6262A (ja) 1986-03-05 1987-01-06 Ishihara Sangyo Kaisha Ltd ベンゾイルウレア系化合物の製造方法
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
EP1438053B1 (de) 2001-10-17 2008-09-10 Boehringer Ingelheim Pharma GmbH & Co.KG Pyrimidinderivate, arzneimittel enthaltend diese verbindungen, deren verwendung und verfahren zu ihrer herstellung
DE10161763A1 (de) 2001-12-15 2003-07-17 Bayer Cropsience Ltd Neues herbizides Verfahren
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
WO2003095448A1 (en) 2002-05-06 2003-11-20 Bayer Pharmaceuticals Corporation Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders
TW200406374A (en) 2002-05-29 2004-05-01 Novartis Ag Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
WO2004048343A1 (en) 2002-11-28 2004-06-10 Schering Aktiengesellschaft Chk-, pdk- and akt-inhibitory pyrimidines, their production and use as pharmaceutical agents
ATE458731T1 (de) 2002-12-20 2010-03-15 Pfizer Prod Inc Pyrimidin-derivate zur behandlung von anormalem zellwachstum
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
DE602004004287T2 (de) 2003-09-05 2007-06-21 Pfizer Products Inc., Groton Selektive synthese von cf3-substituierten pyrimidinen
US20070105839A1 (en) 2003-09-18 2007-05-10 Patricia Imbach 2, 4-Di (phenylamino) pyrimidines useful in the treatment of proliferative disorders
MY141220A (en) 2003-11-17 2010-03-31 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosine kinases
KR100886990B1 (ko) 2004-05-14 2009-03-04 화이자 프로덕츠 인크. 비정상적인 세포성장의 치료를 위한 피리미딘 유도체
EP1598343A1 (de) 2004-05-19 2005-11-23 Boehringer Ingelheim International GmbH 2-Arylaminopyrimidine als PLK Inhibitoren
EP1765791A1 (en) 2004-07-08 2007-03-28 Boehringer Ingelheim Pharmaceuticals Inc. Pyrimidine derivatives useful as inhibitors of pkc-theta
US7521457B2 (en) 2004-08-20 2009-04-21 Boehringer Ingelheim International Gmbh Pyrimidines as PLK inhibitors
US7776869B2 (en) 2004-10-18 2010-08-17 Amgen Inc. Heteroaryl-substituted alkyne compounds and method of use
EP1841760B1 (en) 2004-12-30 2011-08-10 Exelixis, Inc. Pyrimidine derivatives as kinase modulators and method of use
US7323447B2 (en) 2005-02-08 2008-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2006091737A1 (en) 2005-02-24 2006-08-31 Kemia, Inc. Modulators of gsk-3 activity
EP1705177A1 (en) 2005-03-23 2006-09-27 Schering Aktiengesellschaft N-aryl-sulfoximine-substituted pyrimidines as CDK- and/or VEGF inhibitors, their production and use as pharmaceutical agents
JP2008540391A (ja) 2005-05-05 2008-11-20 アストラゼネカ アクチボラグ ピラゾリルアミノ置換ピリミジン、および癌の処置におけるそれらの使用
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US20070032514A1 (en) 2005-07-01 2007-02-08 Zahn Stephan K 2,4-diamino-pyrimidines as aurora inhibitors
ES2391783T3 (es) 2005-10-28 2012-11-29 Astrazeneca Ab Derivados de 4-(3-aminopirazol)pirimidina para su uso como agentes inhibidores de las tirosina cinasas en el tratamiento del cáncer
US8722884B2 (en) 2005-12-01 2014-05-13 Verastem, Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
CA2634646C (en) 2005-12-21 2012-04-10 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
TW200804364A (en) 2006-02-22 2008-01-16 Boehringer Ingelheim Int New compounds
EP2007754A1 (en) 2006-04-10 2008-12-31 Boehringer Ingelheim International GmbH 2, 4-diaminopyrimidine derivatives and their use for the treatment of cancer
US8623887B2 (en) * 2006-05-15 2014-01-07 Boehringer Ingelheim International Gmbh Compounds
JP5301431B2 (ja) 2006-05-18 2013-09-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング キラルな環状β−アミノカルボキサミドの製造方法
DE102006027156A1 (de) 2006-06-08 2007-12-13 Bayer Schering Pharma Ag Sulfimide als Proteinkinaseinhibitoren
US8258129B2 (en) 2006-07-06 2012-09-04 Boehringer Ingelheim International Gmbh 4-heterocycloalkylpyri(mi)dines, process for the preparation thereof and their use as medicaments
DE102006041382A1 (de) 2006-08-29 2008-03-20 Bayer Schering Pharma Ag Carbamoyl-Sulfoximide als Proteinkinaseinhibitoren
WO2008040951A1 (en) 2006-10-03 2008-04-10 Astrazeneca Ab Compounds
US8097630B2 (en) 2006-10-10 2012-01-17 Rigel Pharmaceuticals, Inc. Pinane-substituted pyrimidinediamine derivatives useful as Axl inhibitors
US20080255155A1 (en) 2006-10-18 2008-10-16 Stephane Raeppel Kinase inhibitors and uses thereof
ATE546437T1 (de) 2006-10-19 2012-03-15 Hoffmann La Roche Aminomethyl-4-imidazole
AR063527A1 (es) 2006-10-23 2009-01-28 Cephalon Inc Derivados biciclicos fusionados de 2,4-diaminopirimidina como inhibidores de alk y c-met
WO2008071587A2 (en) * 2006-12-13 2008-06-19 F. Hoffmann-La Roche Ag 2-(piperidin-4-yl)-4-phenoxy- or phenylamino-pyrimidine derivatives as non-nucleoside reverse transcriptase inhibitors
CA2670645A1 (en) 2006-12-19 2008-07-03 Genentech, Inc. Pyrimidine kinase inhibitors
EP1939185A1 (de) 2006-12-20 2008-07-02 Bayer Schering Pharma Aktiengesellschaft Neuartige Hetaryl-Phenylendiamin-Pyrimidine als Proteinkinaseinhibitoren zur Behandlung von Krebs
EP2124951B1 (en) 2006-12-21 2014-05-21 Vertex Pharmaceuticals Inc. 5-cyan0-4- (pyrrolo[2, 3b]pyridine-3-yl) -pyrimidine derivatives useful as protein kinase inhibitors
EP2109605B1 (en) 2006-12-22 2013-02-20 Boehringer Ingelheim International GmbH 2- [(phenylamino) -pyrimidin-4ylamin0] -cyclopentane carboxamide derivatives and related compounds as inhibitors of kinases of the cell cycle for the treatment of cancer
AR065015A1 (es) 2007-01-26 2009-05-13 Smithkline Beecham Corp Derivados de antranilamida, composiciones farmaceuticas que los contienen, y usos para el tratamiento del cancer
US7947698B2 (en) 2007-03-23 2011-05-24 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
JP4782239B2 (ja) 2007-04-18 2011-09-28 ファイザー・プロダクツ・インク 異常細胞増殖治療のためのスルホニルアミド誘導体
AU2008275918B2 (en) 2007-07-17 2014-01-30 Rigel Pharmaceuticals, Inc. Cyclic amine substituted pyrimidinediamines as PKC inhibitors
WO2009017838A2 (en) 2007-08-01 2009-02-05 Exelixis, Inc. Combinations of jak-2 inhibitors and other agents
KR101174201B1 (ko) 2007-08-28 2012-08-16 아이알엠 엘엘씨 키나제 억제제로서의 2-비페닐아미노-4-아미노피리미딘 유도체
WO2009063240A1 (en) 2007-11-16 2009-05-22 Arrow Therapeutics Limited 2,4-diaminopyrimidine derivatives useful as inhibitors of aurora kinase
EP2231620A1 (en) 2007-12-03 2010-09-29 Boehringer Ingelheim International GmbH Diaminopyridines for the treatment of diseases which are characterised by excessive or anomal cell proliferation
EP2220091B1 (en) 2007-12-14 2012-07-25 Ardea Biosciences, Inc. Reverse transcriptase inhibitors
UY31714A (es) 2008-03-20 2009-11-10 Boehringer Ingelheim Int Preparación selectiva de pirimidinas sustituidas
EP2268621A1 (en) * 2008-03-20 2011-01-05 Boehringer Ingelheim International GmbH Regioselective preparation of substituted pyrimidines
PE20100087A1 (es) 2008-06-25 2010-02-08 Irm Llc Compuestos y composiciones como inhibidores de cinasa
MX2010014568A (es) 2008-06-25 2011-03-29 Irm Llc Derivados de pirmidina como inhibidores de cinasa.
TWI458721B (zh) 2008-06-27 2014-11-01 Celgene Avilomics Res Inc 雜芳基化合物及其用途
EP2179992A1 (de) 2008-10-21 2010-04-28 Bayer Schering Pharma Aktiengesellschaft Sulfonsubstituierte Anlinopyrimidinderivative als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
EP2179991A1 (de) 2008-10-21 2010-04-28 Bayer Schering Pharma Aktiengesellschaft Sulfoximinsubstituierte Anilino-Pyrimidinderivate als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
UY32240A (es) 2008-11-14 2010-06-30 Boeringer Ingelheim Kg Nuevas 2,4-diaminopirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones.
TW201024281A (en) 2008-11-24 2010-07-01 Boehringer Ingelheim Int New compounds
AR074210A1 (es) 2008-11-24 2010-12-29 Boehringer Ingelheim Int Derivados de pirimidina como inhibidores de ptk2-quinasa
US8933227B2 (en) 2009-08-14 2015-01-13 Boehringer Ingelheim International Gmbh Selective synthesis of functionalized pyrimidines
US8729265B2 (en) * 2009-08-14 2014-05-20 Boehringer Ingelheim International Gmbh Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives

Also Published As

Publication number Publication date
EA201200282A1 (ru) 2012-09-28
JP5539519B2 (ja) 2014-07-02
EP2464634B1 (en) 2016-11-30
MX2012001469A (es) 2012-02-22
IN2012DN01342A (OSRAM) 2015-06-05
AU2010283713A1 (en) 2012-02-02
CA2767965A1 (en) 2011-02-17
KR20120046248A (ko) 2012-05-09
US8933227B2 (en) 2015-01-13
IL217112A0 (en) 2012-02-29
BR112012002971A2 (pt) 2015-10-13
JP2013501759A (ja) 2013-01-17
CN102471287A (zh) 2012-05-23
NZ597538A (en) 2014-05-30
AR077925A1 (es) 2011-10-05
WO2011018518A1 (en) 2011-02-17
EP2464634A1 (en) 2012-06-20
US20110190499A1 (en) 2011-08-04
CL2012000278A1 (es) 2012-10-12

Similar Documents

Publication Publication Date Title
TW201124385A (en) Selective synthesis of functionalized pyrimidines
AU2023270195B2 (en) 2,3-dihydroquinazolin compounds as NAV1.8 inhibitors
KR102738278B1 (ko) 글루카곤-유사 펩티드 1 수용체 효능제
JP6917988B2 (ja) 血漿カリクレイン阻害薬としてのヘテロアリールカルボキサミド誘導体
TW502034B (en) 2-aryl-8-oxodihydropurine derivative, process for the preparation thereof, pharmaceutical composition containing the same, and intermediate therefor
CA2881351A1 (en) Indole carboxamide derivatives and uses thereof
EP3414234A1 (en) Bruton's tyrosine kinase inhibitors
TW200813043A (en) New chemical compounds
CZ290923B6 (cs) Aromatické sloučeniny, způsoby jejich přípravy a farmaceutické prostředky, které je obsahují
US20160130265A1 (en) Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity
EP2888248B1 (en) Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity
WO2010096722A1 (en) 3-oxo-2, 3-dihydro- [1,2, 4] triazolo [4, 3-a]pyridines as soluble epoxide hydrolase (seh) inhibitors
US12391667B2 (en) N-methyl, n-(6-(methoxy)pyridazin-3-yl) amine derivatives as Autotaxin (ATX) modulators for the treatment of inflammatory airway or fibrotic diseases
US20230022770A1 (en) Novel pyridazines
OA12293A (en) 3-Azabicyclo(3.1.0)hexane derivatives having opioid receptor affinity.
TW200944509A (en) Selective preparation of substituted pyrimidines
CN105541793A (zh) 曲格列汀的合成方法及由该方法合成的曲格列汀以及曲格列汀合成中间体
US20240083896A1 (en) Nitrogen Containing 2,3-Dihydroquinazolinone Compounds as Nav1.8 Inhibitors
JP2013501758A (ja) 2−アミノ−5−トリフルオロメチルピリミジン誘導体の位置選択的調製
JP2023531283A (ja) P2x4受容体拮抗作用を有する置換n-フェニルアセトアミド
CA2529207C (en) 2,4-bis(trifluoroethoxy)pyridine compound and medicine containing the same
JP5536771B2 (ja) セロトニン作動性活性を有する化合物、その製造方法およびそれを含む医薬組成物
JP5061565B2 (ja) ピリミジン化合物の新規製造方法
CN119677723A (zh) 作为选择性hdac6抑制剂的二氟和三氟乙酰基酰肼
OA17445A (en) Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity